Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs

J Clin Oncol. 2023 Nov 10;41(32):4968-4972. doi: 10.1200/JCO.23.01423. Epub 2023 Sep 21.

Authors

Christopher M Booth^{1

2

3}, Elizabeth A Eisenhauer², Bishal Gyawali^{1

2

3}, Ian F Tannock⁴

Affiliations

¹ Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.
² Department of Oncology, Queen's University, Kingston, Canada.
³ Department of Public Health Sciences, Queen's University, Kingston, Canada.
⁴ Division of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada.

PMID: 37733981
DOI: 10.1200/JCO.23.01423

No abstract available

MeSH terms

Antineoplastic Agents* / adverse effects
Disease-Free Survival
Humans
Progression-Free Survival

Substances

Antineoplastic Agents